Nanotechnology Now - Press Release: " INSERTING and REPLACING University of Texas Health Science Center at Houston Releases News of Successful NanoLogix Test: UTHealth researchers say more rapid test for Group B strep successful"

Home > Press > INSERTING and REPLACING University of Texas Health Science Center at Houston Releases News of Successful NanoLogix Test: UTHealth researchers say more rapid test for Group B strep successful

Abstract:
NanoLogix Inc. (OTC: NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria, announces that final results of a 14 month study done by researchers at UTHSC-Houston have been published in a recent online edition of "Infectious Diseases in Obstetrics and Gynecology." The results were also presented at the 33rd annual Society of Maternal Fetal Medicine meeting last month in San Francisco. Researchers tested 356 pregnant patients for Group B Strep using NanoLogix BNF tests during the study, with NanoLogix test results obtained in 6.5 hours as opposed to 48 hours with standard tests.

INSERTING and REPLACING University of Texas Health Science Center at Houston Releases News of Successful NanoLogix Test: UTHealth researchers say more rapid test for Group B strep successful

Hubbard, OH | Posted on March 12th, 2013

Jonathan Faro, MD, PhD, the chief researcher on the study and assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Medical School at Houston, part of UTHealth, stated: "We're very happy at UT to have the recent clinical study on GBS showing positive results with the 6.5 hour test. Even more exciting, however, is that we are now seeing results as fast as 30 minutes. This more rapid test is based on a modification of the 6.5 hour test, and has the potential to allow for antibiotic susceptibility testing in an amount of time that would have previously been considered simply impossible. The studies with GBS have been applied to other bacteria, and we are very pleased to see similar results with gonorrhea, which has been implicated last year as a multi-drug resistant pathogen. We are in the final stages of formalizing the 30 minute test for GBS, and will continue to work on additional applications for this assay."

The news from UTHealth Houston can be found here: http://www.uthouston.edu/media/story.htm?id=e3142cc6-bc5b-415d-8f17-8243da5eb58d

NanoLogix exhibited at the ASM BioDefense and Emerging Diseases Research Meeting in Washington DC 25-27 February 2013. There was strong interest in the Company's technologies at the exhibition. Interested parties included Federal agencies, universities, large and small laboratories, NGO's, and corporations, with resulting sales begun this week.

NanoLogix has contracted with a team of independent marketing specialists to promote the Company's products to key opinion leaders and executives in multiple health and food sectors. The specialist team is composed of current or former directors and managers of various national and international health sector corporations. This event marks the transition of the Company from a primary focus on research and development to one of marketing and production. There will be a continued science emphasis upon water quality test development with the US EPA and also product QA/QC. This new focus will also result in a reallocation of resources with a heavy focus upon increased marketing on multiple fronts.

####

About NanoLogix Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to national defense, medical, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, food quality, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please click here

Contacts:
Investors:
NanoLogix, Inc.
Carol Surrena
330-534-0800

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: